Research Study – Early-stage Non-Small Cell Lung Cancer
Novartis invites eligible lung cancer patients to participate in a research study entitled Early-stage Non-Small Cell Lung Cancer
Have you or someone you know been diagnosed with Non-Small Cell Lung Cancer?
The aim of the study would be to see if the study medication can be of benefit to patients in reducing the risk of cancer reappearance after their lung cancer has been surgically removed and adjuvant chemotherapy had been completed (if applicable). The findings will be used to support application to Regulatory authorities to have the study drug approved for the treatment of Non-Small-Cell Lung carcinoma.
You are eligible to participate in this study if:
➢ You are over 18 years of age
➢ Lung Cancer was/is to be removed with surgery
If you are interested in finding out more or participating in this research, please contact one of the research sites situated in George or Pretoria.
George: Elza Bouwer: 044 884 0806
Pretoria: Neo Monaheng: 012 354 2021/1054
The closing date for recruitment is 16 December 2021
This research has been granted ethical and SAHPRA (South African Health Products Regulatory Authority) approval.